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Brain injury triggers a progressive inflammatory response supported by a dynamic astroglia-microglia interplay.We investigated the
progressive chronic features of the astroglia-microglia cross talk in the perspective of neuronal effects in a ratmodel of hippocampal
excitotoxic injury. N-Methyl-D-aspartate (NMDA) injection triggered a process characterized within 38 days by atrophy, neuronal
loss, and fast astroglia-mediated S100B increase. Microglia reaction varied with the lesion progression. It presented a peak of tumor
necrosis factor-𝛼 (TNF-𝛼) secretion at one day after the lesion, and a transient YM1 secretion within the first three days. Microglial
glucocorticoid receptor expression increased up to day 5, before returning progressively to sham values. To further investigate
the astroglia role in the microglia reaction, we performed concomitant transient astroglia ablation with L-𝛼-aminoadipate and
NMDA-induced lesion. We observed a striking maintenance of neuronal death associated with enhanced microglial reaction
and proliferation, increased YM1 concentration, and decreased TNF-𝛼 secretion and glucocorticoid receptor expression. S100B
reactivity only increased after astroglia recovery. Our results argue for an initial neuroprotective microglial reaction, with a direct
astroglial control of the microglial cytotoxic response. We propose the recovery of the astroglia-microglia cross talk as a tissue
priority conducted to ensure a proper cellular coordination that retails brain damage.
1. Introduction
Injury to the central nervous system, including stroke and
traumatic brain injury, induces excitotoxic neuronal death
that triggers a potent inflammatory response with a dynamic
astroglia andmicroglia reaction that determine neuronal fate
[1, 2]. Following the injury, all cells present ametabolic repro-
gramming to cover the bioenergetic and substrate demand for
the trophic/inflammatory processes to take place [3] with the
coexistence of various factors.
An excessive production of proinflammatory factors from
activated microglia, such as tumor necrosis factor-𝛼 (TNF-
𝛼), interleukin-1𝛽, and reactive oxygen species, may trigger
or exacerbate neuronal death [4]. Microglia do not constitute
a unique cell population and show a range of phenotypes
that are closely related with the evolution of the damaging
process [5, 6]. Thus, their control will directly influence the
tissue outcome [7]. These phenotypes range from the well-
known proinflammatory activation state to a trophic one
involved in cell repair and extracellular matrix remodelling
[8]. In neurodegeneration, for example, microglia show
inflammatory and neuroprotective properties [6] associated
with the expression of YM1, a secretory protein related to
neuroregeneration [9, 10]. In addition, as some microglial
cells become increasingly dysfunctional, they may directly
participate in the development of neurodegeneration [11].
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Whether microglia through TNF-𝛼, interleukin-1𝛽, and
reactive oxygen species formation [4] adopt a phenotype that
mostly exacerbates tissue injury or promotes brain repair
with YM1 and other neuroprotective factors expression [9, 10]
likely depends on the diversity of signals from the lesion
environment, especially at the quadripartite synapse level
[12]. For instance, astroglial chemokines have an influence
upon microglia/macrophage activation in multiple sclerosis
with CCL2 (MCP-1) and CXCL10 (IP-10) directing reactive
gliosis [13]. Although a clear account of this dynamic relation-
ship has yet to be proposed, the astrocyte-microglia interplay
might determine the phenotype that microglia adopt during
neurodegeneration.
Steroid hormones may modulate the microglial response
to injury, although the results are still controversial. Studies
have shown that glucocorticoids regulate peripheral immune
responses and have CNS anti-inflammatory properties, but
they also appear to develop proinflammatory effects that
exacerbate excitotoxicity and cerebral damage (see [14] for a
review). This observed variability may be related to an acute
or chronic CNS effect, with the initial anti-inflammatory
modulation being eventually followed by an exacerbation of
cerebral injury [14]. If this hypothesis is correct, it would
be possible to modulate the cytotoxic and neuroprotective
activity of microglia through acute or chronic activation of
the glucocorticoid receptor (GR), the most abundant steroid
hormone receptor found in microglia [15].
Astroglial S100B is one of those factors that control mi-
croglial activity. Astrocytes release S100B constitutively [16]
and increase this release upon stimulation by several factors,
including TNF-𝛼 [17]. Under normal conditions, released
S100B acts as a neurotrophic factor, countering the stimula-
tory effect of neurotoxins on microglia [18] and stimulating
glutamate uptake [19]. By contrast, at high concentrations
S100B binds the Receptor for Advanced Glycation End
products (RAGE), whichmightmediatemicroglial activation
in the course of brain damage [20].Thus, secreted S100B par-
ticipates in astrocyte-microglia cross talk, with an important
role in the initial phase of brain insults.
The purpose of the present study was to study the rela-
tionship between microgliosis and astrogliosis in an in vivo
model of hippocampal injury that triggers chronic neu-
roinflammation [12]. To this end, we undertook a time-
course study between day 1 and day 38 of a hippocampal
N-methyl-D-aspartate (NMDA) stereotaxic-induced lesion
and we characterized neuronal loss and the astroglial and
microglial reactions. We quantified TNF-𝛼, YM1, 8 kDa
translocator protein (TSPO, or peripheral benzodiazepine
receptor, PBR [21]), and GR at different postlesion times to
estimate the state of microglial activity. Then, to determine
the relationship between astrogliosis and microglia activa-
tion, we coinjected NMDAwith L-𝛼-aminoadipate (𝛼-AA), a
specific astrotoxin used to investigate astroglial participation
in several paradigms (e.g., [22–25]). 𝛼-AA induces a transient
astroglial ablation, which is associated with a microglial
reaction that persists over several days [24, 26, 27]. The
sequence of events described in vivo after 𝛼-AA stereotaxic
microinjection includes astroglial degeneration for 1–3 days,
microglial invasion, and, finally, astroglial recovery [24, 26].
2. Materials and Methods
2.1. Animals. Adult male Wistar rats (body weight 200–
225 g at the beginning of the study) were obtained from
the animal housing facilities at the School of Medicine
(Universitat de Barcelona). They were kept on a 12 h/12 h
day/night cycle and housedwith free access to food andwater.
Animals weremanipulated according to European legislation
(86/609/EEC) and all efforts were made to minimize the
number of animals used and their suffering. The number
of animals to be included in each group was statistically
estimated to be 6 rats/group (tolerance interval ±0.9, con-
fidence level 95%). Procedures were approved by the Ethics
Committee of the Universitat de Barcelona, in accordance
with the regulations established by the Catalan government
(Generalitat de Catalunya).
2.2. Chemicals. NMDA, 𝛼-AA, the mouse monoclonal anti-
glial fibrillary acidic protein (GFAP), and the biotin-con-
jugated isolectin B4 (IB4) from Bandeiraea simplicifolia were
all purchased from Sigma (St. Louis, MO).Themouse mono-
clonal anti-NeuN was purchased from Chemicon (Temecula,
CA), themouse anti-rat CD11b antibody (cloneMRCOX-42)
was fromSerotec Ltd. (Oxford,UK), and the rabbit polyclonal
anti-S100B antibody was from DAKO (Dako Diagnostics,
Barcelona, Spain). The goat polyclonal AMCase (M-19) anti-
body that specifically binds the transcription factor YM1 was
from Santa Cruz Biotechnology (Santa Cruz, CA) as was
the rabbit polyclonal anti-GR antibody. Secondary antibodies
and immunohistochemical reagents were from Sigma.
[3H]PK-11195 was purchased from Perkin-Elmer (Bos-
ton, MA). [3H]Corticosterone was from Amersham Bio-
science (Bucks, UK) and RU-28362 was purchased from
Sigma. Dodecyl sulphate-polyacrylamide gel electrophoresis
standards were purchased from Bio-Rad (Hercules CA),
Immobilon-P membranes were from Millipore (Bedford,
MA), and ECL Plus Western Blotting reagent was from
Amersham Bioscience (Bucks, UK). The murine TNF-𝛼
ELISA development kit was purchased from PeproTech
(Paris, France).
2.3. Stereotaxic Procedure and Labeling of Proliferating Cells.
Under equithesin anesthesia (amixture of chloral hydrate and
sodium pentobarbitone; 0.3mL/100 g body wt, i.p.), rats were
placed in a stereotaxic instrument (David Kopf, Carnegie
Medicin, Sweden) with the incisor bar set at −3.3mm.
According to the Atlas of Paxinos and Watson [28], the
stereotaxic coordinates for the hippocampal microinjection
were 3.3mm caudal to bregma, 2.2mm lateral to bregma,
and 2.9mm ventral from dura. A 5.0𝜇L Hamilton syringe
activated by an infusion pump (CMA/100; CarnegieMedicin,
Sweden) was used for the intracerebral injection into the
hippocampal parenchyma. In all injections 0.5𝜇Lwas infused
over 5min as previously described [29].
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Animals received a single injection of either 50mMphos-
phate buffer saline (PBS; pH 7.4) (sham group), 20 nmol
NMDA in 50mM PBS (NMDA group), 6.4 nmol 𝛼-AA (𝛼-
AA group), or 20 nmol NMDA plus 6.4 nmol 𝛼-AA (NMDA
+ 𝛼-AA group). At five different postlesion times (1, 3, 5,
15, and 38 days) a total of 60 rats, 12 for each group (sham,
𝛼-AA, NMDA, and 𝛼-AA + NMDA) and 12 control rats
(with no treatment, assigned as 0 days), were anaesthetized
and decapitated. Half of the animals (6 rats/group) were
used for biochemical studies and the other half were used
for histological approaches. The NMDA dose was chosen
according to previous studies [29]. As it was used in low
concentrations, sodiumpentobarbitone did not interferewith
the function of NMDA receptors [29]. 𝛼-AA was at the limit
of its solubility in water (2.2mg/mL) and the selected dose
ensured a specific gliotoxic effect [24].
2.4. Histology, Immunohistochemistry, and Image Analysis.
At the indicated postlesion time, six rats from each group
were anaesthetized and decapitated. Their brains were then
quickly removed, frozen with powdered dry ice, and stored
at −80∘C until use. Adjacent 14 𝜇m coronal serial sections at
the level of the dorsal hippocampus (−3.3mm to bregma)
were obtained from all brains, mounted on slices, and
processed for histology, immunohistochemistry, and in vitro
autoradiography studies.
Standard Nissl staining was performed to evaluate neu-
ronal loss and the morphology of the hippocampal region.
Microglial cell shapes were identified by histochemistry with
biotin-conjugated IB4 [30]. Briefly, endogenous peroxidase
activity was inhibited by a 10-minute preincubation in
H
2
O
2
-methanol-PBS (0.3/9.7/90) followed by a 10-minute
wash in PBS [31] and postfixation for 10min with ice-
cold paraformaldehyde (4% in PBS, pH 7.4). Then sections
were incubated overnight at 4∘C with IB4 diluted 1 : 25
in normal goat serum (1 : 100 v/v in 0.01M PBS; pH 7.4).
After incubation with ExtrAvidin (1 : 250), sections were
developed in a 0.05M Tris solution containing 0.03% (w/v)
diaminobenzidine and 0.006% (v/v) H
2
O
2
.
Immunohistochemistry was carried out by the biotin-
avidin-peroxidase method. Astroglial reaction was assessed
by immunodetection with mouse monoclonal anti-GFAP
and rabbit polyclonal anti-S100B antibodies diluted 1 : 400
and 1 : 800, respectively. Neuronal staining andGR expression
were evaluated, respectively, with mouse monoclonal anti-
NeuN antibody (1 : 150) and rabbit polyclonal anti-GR anti-
body (1 : 750). In brief, endogenous peroxidase activity was
inhibited by a 10-minute preincubation in H
2
O
2
-methanol-
PBS (0.3/9.7/90) followed by a 10-minute wash in PBS. Then,
after postfixation for 10min with ice-cold paraformaldehyde
(4% in PBS, pH 7.4), sections were incubated overnight at
4∘C with the primary antibody at the appropriate dilution
in 0.05M PBS containing 0.5% Triton ×100, 1% normal goat
serum, and 1% bovine serum albumin. After washing and
incubating with the appropriate secondary antibody, sections
were incubated with ExtrAvidin (1 : 250) and developed in
diaminobenzidine and H
2
O
2
.
Double immunohistochemistry with specific cellular
markers was performed to determine the cells expressing glu-
cocorticoid receptors. Sections were coincubated overnight
at 4∘C with the rabbit polyclonal anti-GR antibody (1 : 750)
and either mouse monoclonal anti-NeuN antibody (1 : 250)
for neurons, mouse monoclonal anti-GFAP antibody (1 : 750)
for astroglial cells, or mouse monoclonal anti-CD11b (1 : 100)
for microglia. After washing, sections were sequentially
incubated in the dark with goat anti-mouse IgG Alexa Fluor-
555 conjugated (1 : 300) to detect cellular phenotype and then
with biotinylated goat anti-rabbit IgG (1 : 200) followed by
FITC-conjugated ExtrAvidin (1 : 250) to detect GR.
All double immunostained sections were mounted in
ProLong antifade and kept in the dark. Incubations with
either mouse or goat IgG as primary antibodies were used
for negative controls. Confocal images were acquired using
a Leica TCS SL laser scanning confocal spectral micro-
scope (Leica Microsystems Heidelberg GmbH, Manheim,
Germany).
Morphological and histological parameters were mea-
sured in 14 𝜇m thick serial coronal sections with the optical
microscope software AxioVision 4 AC (Zeiss) and analyzed
by the Image Pro Plus v.5.1 image analysis system (Media
Cybernetics Inc., Bethesda, MD, USA). The hippocampal
formation (HF) size, the area occupied by the neuronal
loss, and the different hippocampal subfield areas were
measured on Nissl stained sections at the injection level that
allows differentiating between structures and identifying the
damage to be accurately quantified.The area of hippocampus
occupied by reactive astroglia or microglia was measured
by delimitation of the increased immunoreactivity region
on adjacent GFAP-immunostained, S100B-immunostained,
and IB4-stained sections, respectively, using the same system
[24]. Area size determinations were performed in three
different stained sections at the injection level of all rat
brains. To minimize biased errors due to fronto-occipital
hippocampal size variations, only those sections located
near the injection site and at similar bregma level were
selected for quantification. Then, the area of interest was
referred to as the whole HP area measured in each of
the GFAP-immunostained, S100B-immunostained, and IB4-
stained sections analyzed.Measurement of the wholeHP area
was also used to calculate the ratio between total HF and the
area of gliosis. In all cases the contralateral hippocampus was
measured in the same sections in order to estimate the effects
of histological procedures on tissue size and thus to correct
for variability in individual brain size and tissue shrinkage
[32]. GFAP/S100B expression areas were estimated by the
quotient of the increased immunoreactivity region in GFAP-
and S100B-immunostained sections of each rat.
Neuronal cell counting was performed in NeuN immun-
ostained sections. Under the optical microscope, we ran-
domly selected four areas of interest (1.0mm2 each) from
the dorsal hippocampus. Inside of these areas, we counted
the number of stained cells at a ×40 objective magnification.
Cell counting was performed in duplicate in three differ-
ent stained sections of all rat brains. Immunopositive cells
were counted in all lesioned hippocampal subfields, and
quantification was made in the Image Pro Plus v.5.1 image
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and analysis system. To allow for quantification of double
immunostained cells, multiple epifluorescent partial images
of each hippocampus were taken and mounted in order to
reconstruct an image of the whole structure using a Leica
DMI 6000B inverted microscope equipped with the Tile
Scan function of the LAS AF Leica software (Leica Micro-
systems Heidelberg GmbH, Manheim, Germany). Counting
of double-immunostained cells was performed in duplicate
in three different stained sections of all rat brains as ex-
plained above. GR density was analysed densitometrically
in bright field microscopy images taken from three adjacent
GR immunostained sections [33] from the lesioned hippo-
campus. To do that, we used the same procedure and image
analysis system as described above forNeuN immunopositive
cells. The size and shape of the cell soma were used to dis-
criminate between neurons and glial cells [33] (Figure 2(a)).
For validation of this counting, the number of double
immunopositive cells was also calculated in NeuN-GR and
CD11b-GR double stained sections as explained above for the
estimation of the number of proliferating cells.
2.5. In Vitro Autoradiography. Adjacent sections were pro-
cessed for in vitro autoradiography to assess the hippocampal
distribution of TSPO and GR. TSPO was labeled with
[3H]PK-11195 as a microglial marker. Tissue sections were
incubated for 2 h at room temperature in 50mM Tris-
HCl (pH 7.7) containing 1 nM [3H]PK-11195 (85 Ci/mmol).
Nonspecific binding was determined in the presence of 1 𝜇M
PK-11195. It was homogeneous and lower than 10% of the
total binding. Glucocorticoid receptors were labelled with
10 nM [3H]corticosterone (79Ci/mmol) added to a buffer
solution containing 20mMTris-HCl (pH 7.4), 1.5mMEDTA,
140mM NaCl, and 5mM glucose. 5 𝜇M RU-28362 was used
to discriminate between GR and mineralocorticoid receptor
specific [3H]corticosterone binding [34]. The nonspecific
binding was determined by incubation with 20 𝜇M corticos-
terone and was lower than 20% of total binding.
After washing in the appropriate buffer, slides were
dried overnight under a stream of air at 4∘C and opposed
to Hyperfilm-3H (Amersham) for a period between two
weeks and two months. Films were developed and analysed
densitometrically after calibrationwith plastic standards (3H-
Microscales, Amersham) using the Image Pro Plus v.5.1 image
analysis system. The average brain protein content was 8%.
For each brain, four sections were processed for total binding
and two other sections for nonspecific binding.
2.6. Western Blot and Immunoassay. At the indicated post-
lesion time, six rats from each group were anaesthetized
and decapitated. The brain of each animal was removed and
the HF dissected, before being quickly frozen in liquid N
2
and stored at −80∘C prior to use. Each HF was manually
homogenized in ice-cold Tris-HCl 50mM, pH 7.7, containing
2mM EDTA and a protease inhibitor cocktail. Part of the
homogenate was immediately ultrasonicated at 4∘C with a
Sonifier 250 (Branson, Ultrasonic Corp., Danbury, CT) and
centrifuged; the supernatant was directly used for TNF-𝛼
immunoassay. The other part was ultracentrifuged at
15000 rpm for 15min at 4∘C and the supernatant (cytosolic
fraction) was used for Western blot analysis of YM1 protein.
In both cases, protein determination was carried out using
the Bradford method.
Western blot analysis was performed as described else-
where, with specific antibodies against YM1 [10]. Low-range
molecular weight biotinylated SDS-PAGE standards were run
in each gel to ascertain the position of each band. Immobilon-
P was used for electroblotting and the immunocomplexes
were detected by enhanced chemiluminescence using the
ECL Plus Western Blotting Kit. Films were then developed,
scanned, and analysed densitometrically with the Image Pro
Plus v.5.1 image analysis system.
TNF-𝛼 was quantified with the murine TNF-𝛼 ELISA
development kit as indicated by the supplier protocol. In all
samples, TNF-𝛼 determination was performed in duplicate.
2.7. Statistical Analysis. For each parameter, kurtosis and
skewness moments were calculated to test the normal dis-
tribution of data. A two-way ANOVA was performed with
two factors: time with six levels (0 days, 1 day, 3 days, 5 days,
15 days, and 38 days) and treatment with four levels (sham,
𝛼-AA, NMDA, and NMDA + 𝛼-AA). When significant two-
way interactionswere observed, individual comparisonswere
performed using one-way ANOVAs followed by the LSD
post hoc test. Single comparisons between sham and NMDA
groups at one time point were made using the Student’s 𝑡-test
(𝑡).When normality was not achieved, the values of all groups
were compared using the nonparametric Kruskal-Wallis test
(KW) followed by theMann-Whitney𝑈 test (KS). In all cases,
𝑃 < 0.05was considered as statistically significant. Results are
expressed as mean ± SEM. All analyses were performed with
the STATGRAPHICS software (STSC Inc., Rockville, MD,
USA).
3. Results
3.1. NMDA Induced Fast, Enduring Microgliosis with Phe-
notype Changes within Fifteen Days. Observation of Nissl-
stained sections revealed that 20 nmol NMDA produced
major layer disorganization, neuronal loss, and gliosis in all
layers of the hippocampal formation (HF). Animals from
the sham group showed no cellular alterations except for the
needle scar (Figure 1(a)). The hippocampal lesion extended
within 2mm around the injection site in the rostrocaudal
axis, with a slight tendency to grow towards the caudal
direction. In the NMDA group (Figure 1(b)), we observed an
increase in the area of lesion as a consequence of an initial
massive neuronal loss within the first 3 days, followed by a
more discrete neuronal death that still progressed at 38 days
(Figure 1(c)).
Histochemistry analysis with IB4 stained hyperplasic
and hypertrophic microglia in all NMDA-lesioned animals
(Figure 1(e)). The reactive microglia area increased with time
and reached a maximal value at 15 days, with this value
being maintained at day 38 (Figure 1(g)). Quantification
of the TSPO microglial expression by [3H]PK-11195 using
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Figure 1: Timing of the microglial reaction to NMDA in the hippocampus. Photomicrographs illustrate the hippocampal injury and
microglial reaction to NMDA-induced lesion at the injection site. Photomicrographs of cresyl-violet stained brain sections of (a) sham rats
and (b) NMDA rats 15 days after the lesion. (c) Graph shows the quantification of the area of lesion relative to the whole HF in cresyl-violet
stained sections. IB4 histochemistry of sham (PBS) (d) and NMDA rats (e) 15 days after the lesion. (f) Distribution of specific binding sites
for [3H]PK-11195 in a coronal rat brain section 15 days after 20 nmol NMDA injection. Note the NMDA-induced increase of specific binding
(arrowhead) seen as a white area in the left hippocampus. Graphs show the quantification of the area of microglial reaction in IB4-stained
sections (g), the area of enhanced [3H]PK-11195 specific binding (h), and the hippocampal concentration of TNF-𝛼 (i) of PBS andNMDA rats
during the 38 days of the study. Asterisks in (a), (b), (d), and (e) indicate the injection site. CA1, Cornu Ammonis area 1; DG, dentate gyrus.
∗
𝑃 < 0.05 different from PBS; #𝑃 < 0.05 different from day 0 (LSD post hoc test in (d), (f); KW test in (e)) (𝑛 = 6 PBS; 𝑛 = 6 NMDA rats).
Bar: 1mm in (a), (b), (d), and (e) and 2mm in (f).
in vitro autoradiography (Figure 1(f)) also showed an area
of microglial reaction to the NMDA injection into the hip-
pocampus (Table 1). In the NMDA-lesioned versus the sham
groups both the intensity (Table 1) and the area (Figure 1(f))
of [3H]PK-11195 binding density showed an increase between
day 1 and day 38 (Figure 1(h)). The sham group showed
[3H]PK-11195 specific binding that was increased in the
injection site only in a small area on day 1.
The TNF-𝛼 concentration increased in both sham and
NMDA-lesioned groups only within the first five days of the
lesion (Figure 1(i)). Between days 1 and 3, the concentration
of TNF-𝛼 in the NMDA group increased with respect to
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Table 1: [3H]11195 and [3H]corticosterone specific binding to brain sections after 20 nmol NMDA injection in the hippocampus.
0 days 1 day 5 days 15 days 38 days
Specific TSPO binding
Sham hippocampus 481 ± 98 1532 ± 107# 618 ± 187 483 ± 341 483 ± 102
NMDA hippocampus 480 ± 73 1495 ± 189* 1644 ± 255*# 1571 ± 346*# 1440 ± 235*#
Parietal cortex 490 ± 11 474 ± 64 472 ± 40 473 ± 18 488 ± 9
Piriform cortex 468 ± 5 439 ± 35 425 ± 33 453 ± 37 465 ± 2
Specific GR binding
Sham hippocampus 68 ± 72 101 ± 94 74 ± 37 81 ± 13 75 ± 21
NMDA hippocampus 76 ± 62 198 ± 104 448 ± 247*# 91 ± 23 105 ± 32
Parietal cortex 101 ± 19 102 ± 14 85 ± 19 77 ± 32 102 ± 20
Piriform cortex 103 ± 24 74 ± 19 89 ± 6 73 ± 3 102 ± 42
18 kDa translocator protein (TSPO) concentration was estimated by [3H]PK11195 specific binding. 5 𝜇M RU-28362 allowed discriminating the
[3H]corticosterone specific binding to glucocorticoid receptors (GR). Data are expressed in fmol/mg of protein (mean ± S.E.M). *𝑃 < 0.05 different from
0 days; #𝑃 < 0.05 different from sham values (KW test).
the sham group and progressively returned to initial values
by day 38. In the sham group, we only found a small transient
increase in TNF-𝛼 concentration at day 3.
We quantified the time-related changes of glucocorti-
coid receptor (GR) concentrations in the hippocampus by
immunohistochemistry (Figure 2) and by in vitro autora-
diography of [3H]corticosterone binding (Table 1). In the
sham group, single immunohistochemistry of GR showed
widespread staining in the hippocampus and adjacent areas.
We observed an increased GR-immunoreactivity (GR-IR) in
the lesioned HF mostly in the nucleus of glial cells and sur-
viving neurons between days 1 and 5 after NMDA injection
(Figures 2(a) and 2(b)). Double immunohistochemistry and
confocal analysis of anti-GR antibody with either anti-NeuN,
anti-GFAP, or anti-CD11b antibodies evidenced short-term
GR distribution changes in surviving neurons and reactive
microglia but not in reactive astrocytes (Figures 2(c)–2(t)).
We found the more evident GR-IR increase in the nucleus
of round-shaped CD11b-immunostained cells at day 5 after
the lesion (Figures 2(o)–2(t)), whereas the weak GR labeling
of most GFAP-immunopositive cells remained and only a
few scattered cells showed increased nuclear staining (Figures
2(i)–2(n)).
We calculated the nucleus/cytoplasm GR-IR ratio as
an estimation of GR activation, as unactivated GR pre-
dominantly localized within the cytoplasm and migrates
to the nucleus with hormone binding. At day 1 the
nucleus/cytoplasm GR-IR ratio was strongly increased in
neurons of the lesioned CA1 strata and remained increased
only at day 5.We foundmarked differences inmicroglial cells
(Figure 2(b)). In these cells, the nucleus/cytoplasm GR-IR
ratio increased at days 1 and 5 after NMDA microinjection
to then gradually decrease to sham group values at day 38.
Experiments with [3H]corticosterone specific binding to
GR showed low levels in theHF and the parietal and pyriform
cortex of sham animals (Table 1). In the hippocampus of
NMDA-lesioned rats, [3H]corticosterone specific binding
progressively increased reaching a maximal value of 448 ±
247 fmol/mg prot at day 5 to then decrease to sham levels at
day 15 (Table 1).
3.2. Within Fifteen Days 𝛼-AA Did Not Modify NMDA-
Mediated Neuronal Loss. Stereotaxic Injection of 20 nmol
NMDA produced major neuronal loss mainly in the CA1
layers (Figures 3(a)–3(c)).The area of neuronal loss extended
to 34 ± 5% of the pyramidal CA1 within the first three days
(Figure 3(g)) and then progressively increased to reach a
maximal value at day 38. The same pattern was observed
in the neuronal density measured in NeuN immunostained
sections (Figure 3(j)).
Whenwe coinjected 6.4 nmol𝛼-AAwith 20 nmolNMDA
(𝛼-AA + NMDA rats) all the lesion parameters were similar
in all hippocampal strata of the NMDA and 𝛼-AA + NMDA
groups during the first five days (Figures 3(d)–3(f)). In
the 𝛼-AA + NMDA group, we observed increased tissue
disorganization at day 15 and this area of lesion reached
a maximal value at day 38 (Figures 3(d)–3(f)). At all time
points, neuronal density in the HF of 𝛼-AA + NMDA and
NMDA groups was similar (Figures 3(j)–3(l)).
The injection of 6.4 nmol of 𝛼AA alone caused no change
in the hippocampal size, lesion area, or neuronal density
when compared with sham group values at any of the studied
time points (Figures 3(g)–3(i)).
3.3. 𝛼-AA Enhanced the S100B/GFAP Ratio Three Days after
the NMDA-Induced Lesion. The treatment only with 𝛼-AA
induced a loss in the GFAP-immunoreactivity (IR) in a small
area of the hippocampus around the injection site that was
already recovered at day 3 after injection (Figures 4(a)–4(d)).
In the NMDA group, the GFAP-IR increase was maximal
at day 13 (Figures 4(c) and 4(d)) and then progressively
decreased by day 38. In the 𝛼-AA + NMDA group only a
few astrocytes showed a weak reactive morphology at day 1
(Figures 4(e)–4(h)). At day 3, the area of enhanced GFAP-
IR covered 29 ± 7% of the HF (Figure 4(i)), which increased
slightly by day 38 to reach similar values to those obtained
in the NMDA group at this time point. At day 38, reactive
hippocampal astrocytes of 𝛼-AA + NMDA rats presented
enhanced hypertrophy and hyperplasia and stronger GFAP-
IR than did those of the NMDA group (Figures 4(l) and
4(m)).
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Figure 2: Activation of glucocorticoid receptors (GR) induced by NMDA injection in the hippocampus. (a) Photomicrographs illustrate GR
immunohistochemistry in the hippocampus of shamanimals andNMDArats 5 days after the injection.Asterisks indicate the injection site and
insets illustrate the GR immunostaining in neurons (arrow) and glial cells (arrowheads). Please note that pyramidal cells (arrows) are much
bigger than glia (arrowheads); they also present a pyramidal shape with a dendritic tree, while reactive microglia have a round smaller shape.
(b) Graphs show the quantification of the nucleus/cytoplasm ratio of GR-immunolabeling in hippocampal neurons and glial cells of sham
(PBS) and NMDA-lesioned rats. Confocal photomicrographs show the double immunohistochemistry of GR (in green) with specific cellular
markers (in red) in the hippocampal CA1 layer of NMDA-lesioned rats 5 days after the lesion. NeuN-GR double immunostaining of PBS
(c–e) and NMDA (f–h) rats evidences an increased GR-immunolabeling in the nucleus of neurons of NMDA rats (arrowheads). GFAP-GR
double immunostaining in PBS (i–k, arrowheads) and NMDA (l–n) rats shows an increased GFAP-immunolabeling in astrocytes of NMDA
rats not associated with GR-immunoreactivity changes, which indicates that the NMDA-induced GR activation quantified in panel (b) is not
astroglial. CD11b-GR double immunohistochemistry in PBS (o–q) and NMDA (r–t) rats evidences an increased GR-immunolabeling in the
nucleus of reactive microglia of NMDA rats. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 different from PBS (Student’s 𝑡-test) (𝑛 = 6 rats/group). Bar: 500 𝜇m in
(a) and 10 𝜇m in (c)–(t) and insets in (a).
Experiments of immunohistochemistry with S100B
showed a very small area of increased IR that corresponded
to the area of GFAP-IR loss, at day 1 in the 𝛼-AA group.
In the NMDA rats, S100B-IR was maximal at day 1 and
then progressively decreased by day 38, following the same
dynamics as GFAP-IR did (Figures 4(j), 4(n), and 4(o)).
In the 𝛼-AA + NMDA group the increased S100B-IR area
was not different to sham group at day 1, and it reached
a maximal value at day 3, before progressively decreasing
to values similar to the NMDA group at day 38. When we
calculated the ratio between S100B and GFAP (S100B/GFAP,
Figure 4(k)) we found similar values between the sham and
NMDA groups, whereas we found a significant increase in
the 𝛼-AA + NMDA at days 3, 5, and 15 (Figure 4(k)). We
found no expression of S100B in microglia using double
immunohistochemistry and confocal analysis of anti-S100B
with anti-CD11b antibodies (data not shown).
3.4. 𝛼-AA Increased NMDA-Induced Microgliosis and YM1
Production Three Days after the Lesion. In the 𝛼-AA group,
the histochemistry with IB4 stainedmorphologically reactive
microglia already at day 1 in an area that reached a maximal
value at day 3, before decreasing to sham group values at
day 38 (Figure 5(a)). In NMDA-lesioned group the area
of microglial reactivity reached significance at day 1 and
increased by day 15 and then decreased at day 38 (Figure 5(a)).
In the 𝛼-AA + NMDA group, microglial reactivity was
already significant at day 1 and covered a maximal area at
day 3, to then progressively decrease at day 38 (Figure 5(a)).
At days 1 and 3, reactive microglia of the 𝛼-AA + NMDA
group presented a ramified morphology clearly different to
the shape showed by microglial cells of the NMDA group,
which presented clear reduction of processes (Figures 5(b)
and 5(c)).
We assessed the TNF-𝛼 concentration in hippocampus by
ELISA. In the HF of 𝛼-AA group, the TNF-𝛼 concentration
was increased at days 1 and 5 when compared with sham
group values (Figure 5(d)). In the NMDA group the TNF-𝛼
concentration in theHF increased at day 1 and it wasmaximal
at day 3 and then it decreased at day 5. In the 𝛼-AA + NMDA
group, TNF-𝛼 concentration was significantly lower than in
the NMDA group (Figure 5(d)).
We assessed the YM1 concentration in hippocampus by
Western blot. YM1 concentration was similarly enhanced in
the 𝛼-AA and NMDA groups when compared with sham
group values (Figure 5(e)). In the 𝛼-AA + NMDA group, the
YM1 concentration was significantly higher compared with
all groups for days 1 and 3, reaching a maximal increase at
day 3 when compared with sham group (Figure 5(e)).
With respect to the nucleus/cytoplasm ratio of GR-IR in
microglia, it was similarly increased in the 𝛼-AA and 𝛼-AA
+ NMDA groups when compared with sham group values at
day 3, whereas this increase was higher in the NMDA group
(Figure 5(f)).
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Figure 3: 𝛼-AA effect on the NMDA-induced hippocampal lesion. Photomicrographs of cresyl-violet stained brain sections of sham rats.
(a) NMDA rats 15 days (b) and 38 days after the lesion (c). 𝛼-AA rats (d) and 𝛼-AA + NMDA rats 15 days (e) and 38 days after the lesion
(f). Asterisks indicate the injection site. Graphs (g) to (i) show the quantification of the area of neuronal loss in cresyl-violet stained sections
in the pyramidal CA1 (g), pyramidal CA2-CA3 (h), and dorsal dentate gyrus (i) of sham (PBS), 𝛼-AA, NMDA, and 𝛼-AA + NMDA rats at
postlesion days 1, 3, 15, and 38. Graphs (j) to (l) show the estimation of the density NeuN immunopositive neurons in the pyramidal CA1 (j),
pyramidal CA2-CA3 (k), and dorsal dentate gyrus (l) of the same rats. ∗𝑃 < 0.05 different from PBS; #𝑃 < 0.05 different from NMDA (LSD
post hoc test) (𝑛 = 6 rats/group). Bar: 500 𝜇m.
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Figure 4: 𝛼-AA effect on the NMDA-induced astroglial reaction in the hippocampus. GFAP-immunostaining 1 (a) and 3 days (b) in sham
animals, 1 (c) and 3 days (d) after 𝛼-AA, 1 (e) and 3 days (f) after NMDA lesion, and 1 (g) and 3 days (h) after 𝛼-AA + NMDA injection
(arrowheads show the injection site). Please note in (c) and (g) the lack ofGFAP-immunopositive cells in the surroundings of the injection site.
Graphs show the quantification of the area of astrogliosis in the whole hippocampus. (i) GFAP-immunostained and S100B-immunostained (j)
sections of sham (PBS), 𝛼-AA, NMDA, and 𝛼-AA +NMDA rats at postlesion days 1, 3, 15, and 38. (k) Graph shows the estimation of the ratio
S100B/GFAP, calculated as the quotient between the area of increased S100B and the area of increased GFAP in these rats. Photomicrographs
illustrate GFAP-immunoreactive cells of NMDA (l) and 𝛼-AA + NMDA (m) rats and S100B-immunoreactive cells of MNDA (n) and 𝛼-AA
+ NMDA (o) rats in the hippocampal parenchyma 3 days after the lesion. ∗𝑃 < 0.05 different from PBS; #𝑃 < 0.05 different from NMDA;
$
𝑃 < 0.05 different from day 15 (LSD post hoc test) (𝑛 = 6 rats/group). Bar: 1mm in (a)–(h) and 10𝜇m in (l)–(o).
4. Discussion
Brain NMDA microinjection triggers an excitotoxic process
that expands through several dynamic processes resulting
in astro- and microglial reactions and a massive neuronal
loss [29] that may involve recruitment of peripheral neu-
trophils and macrophages [35]. The acute excitotoxic process
is thought to be under control by retaliatory mechanisms
within 15 days, but an underlying long-term process of at
least 38 days goes on, associated with tissue atrophy, neu-
ronal loss, and chronic microgliosis, in absence of astroglial
reaction [32]. The microglia response may initially course
with neuroprotective effects to afterwards cause neuron
injury or death [2]. Thus, interventions that promote the
regeneration of damaged tissue long after injury should take
into consideration this dynamic phenomenon, in particular
those addressed to interfere the neuroinflammatory pathways
[7, 36, 37].
Although astrocytes present neuroprotective activity
against excitotoxicity [24], we herein found that early
astroglia ablationwith𝛼-AAdoes not enhancewithin the first
15 days the NMDA-induced hippocampal lesion.The injured
hippocampal area in particular CA2 and CA3 subfields only
increased at day 38. In parallel, 𝛼-AA increased the NMDA-
inducedmicroglia reaction from day 1 on.These results argue
for an early potentiation ofmicroglia neuroprotective activity
while astrocytes are compromised [38].
Our results of IB4 histochemistry and TSPO labelling
by in vitro autoradiography evidenced an early microglial
activation that persisted at least for 38 days during which
TNF-𝛼 secretion and YM1 and GR genes expression followed
different patterns of activation. Specifically, the decrease of
the initial massive production of TNF-𝛼 did not parallel
the morphological long-term activation, YM1 secretion took
place transiently during the first three days of the lesion, and
GR translocation to the nucleus increased progressively up
to day 5 before decreasing to control level. Since microglial
phenotype results from the compromise between cytotoxic
and trophic activities [1], these patterns result from the
evolution of the microglial role during excitotoxicity.
The production of YM1 in the first five days of the lesion
is related to a neuroprotective activity [9], as evidenced in
the olfactory bulb axotomy that results in YM1 secretion that
reduces the inflammatory process [39]. By contrast, TNF-
𝛼 production and GR translocation to the nucleus reflect
more complex roles of microglial activity. TNF-𝛼 secretion is
crucial for autocrine fast microglial activation with cytotoxic
effects, a process also fed with the concomitant release of
TNF-𝛼 by reactive astrocytes [40, 41]. However, the absence
of TNF-𝛼 in knockout mice delays NO-mediated microglial
activation, resulting in further exacerbated microgliosis [20]
that leads to amplification of secondary excitotoxicity. TNF-𝛼
can bind to two specific receptors: TNFR1, with an intracel-
lular death domain, and TNFR2, with a higher affinity and
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Figure 5: 𝛼-AA effect on the NMDA-induced microglial reaction in the hippocampus. (a) Quantification of the hippocampal area of
microglial reaction in IB4-stained sections of sham (PBS), 𝛼-AA, NMDA, and 𝛼-AA + NMDA rats at postlesion days 1, 3, 15, and 38.
Photomicrographs show hippocampal IB4-stained cells illustrating different microglial morphology betweenNMDA (b) and 𝛼-AA +NMDA
(c) rats 3 days after the lesion. (d) TNF-𝛼 hippocampal concentration in PBS, 𝛼-AA, NMDA, and 𝛼-AA + NMDA rats during the first 5 days
of the study. (e) Immunoblots and densitometric analysis (graphs) of YM1 in the hippocampus of PBS, 𝛼-AA, NMDA, and 𝛼-AA + NMDA
rats during the first 5 days of the study. Values were normalized to 𝛽-actin bands. (f) Quantification of the nucleus/cytoplasm ratio of GR-
immunolabeling in hippocampal glial cells 3 days after the lesion of the four groups of the study. P, PBS; A, 𝛼-AA; N, NMDA; NA, 𝛼-AA +
NMDA; ∗𝑃 < 0.05 different from PBS; #𝑃 < 0.05 different fromNMDA; $𝑃 < 0.05 different from 𝛼-AA (LSD post hoc test in (a), (e); Student’s
𝑡-test in (d), (f)) (𝑛 = 6 rats/group). Bar: 10 𝜇m.
mostly involved in neuroprotection [42]. Consequently, at
low concentration TNF-𝛼 activates TNFR2-mediated neuro-
protection, whereas at high concentration TNFR1 contributes
to cell injury [43]. Similarly, at baseline concentration and
as the immediate response to acute stress, glucocorticoids
produce an anti-inflammatory activity over microglia [44].
However chronic high concentration of glucocorticoids exac-
erbates cytotoxic microgliosis and increases hippocampal
injury due to excitotoxicity or ischemia [14]. Such a sus-
tained elevated glucocorticoid concentration downregulates
GR microglia expression as a prerequisite to specifically
inhibit the anti-inflammatory actions [15]. Therefore, the
early activation and posterior downregulation of microglial
GR herein observed may enhance microglia cytotoxic and
inflammatory activity.
S100Bmodifies astrocytic, neuronal, andmicroglial activ-
ities, and its effects depend on both its own extracellular
concentration and the expression of the receptor RAGE.
In activated microglia, S100B at micromolar concentrations
upregulates interleukin-1𝛽 and TNF-𝛼 expression via RAGE
[45], while at nanomolar concentrations S100B blocks that
expression [18]. In turn, microglial reactive oxygen species,
or TNF-𝛼, modify the RAGE response to S100B [17], in
a context of microglia-astroglia cross talk that integrates
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different signaling systems. In this regard, our results suggest
that factors associated with hippocampal excitotoxic injury
may trigger an early trophic neuroprotective reaction in
microglia. Afterwards, variations in the concentration of
these same factors may turn the chronic microgliosis into a
proinflammatory cytotoxic activity.
The ablation of astroglia using 𝛼-AA results in a similar
pattern of NMDA-induced hippocampal damage. 𝛼-AA did
notmodify the NMDA-induced hippocampal lesion area and
neuronal loss during the first fifteen days, and we detected
a discrete increase of these lesion parameters only in the
CA2 and CA3 subfields at day 38, when astroglia was fully
recovered. The 𝛼-AA-induced potentiation of microgliosis
that we found in these conditions supports an early neu-
roprotective microglial activity [46]. As previously shown
[24, 46], 𝛼-AA inhibits the main astroglial pathways of
glutamate removal resulting in increased synaptic glutamate
and increase of oxidative stress [23, 24, 26, 47], which con-
stitute activation signals to microglia. This initial microglial
phenotype may represent an attempt to preserve neurons
during astroglial dysfunction.The activatedmicroglia express
glutamine synthetase and the glutamate transporter 1 in
the early stages of excitotoxicity [47]. Microglial glutamate
uptake starts at 4 h and lasts up to 72 h after the lesion
[48], which indicates that reactive microglia may account
for the control of synaptic glutamate homeostasis after early
astrocyte injury. Furthermore, the early increase of YM1
concentration in the HF of 𝛼-AA + NMDA rats also suggests
a neuroprotective microglial activity that may potentiate the
recovery of astrocytes as indicates the slight enhancement
of GFAP concentration herein found at day 3 in 𝛼-AA
rats.
Initially the 𝛼-AA + NMDA lesion presented a decreased
TNF-𝛼 concentration and a delay in the increase of S100B.
Also, within the first three days, reactive microglia pre-
sented a morphological transition from a phagocytic to
a ramified shape. Thus, when astrocytes are depleted, the
retaliatory mechanisms against excitotoxicity would include
the enhanced neurotrophic activity of the microglia to
counteract the limited functional capacity of the regenerating
astrocytes. Taken together, these data indicate a priority to
recover the astrocyte-microglia cross talk before the astroglial
cytoskeletal rearrangement and proliferation.
From day 3, our results in 𝛼-AA + NMDA rats showed
a sustained reaction of microglia and a heightened S100B/
GFAP ratio that resulted in an increased area of lesion that
reachedCA2 andCA3 hippocampal subfields at day 38 but no
changes in the neuronal density of the lesioned CA1 subfields.
These results also suggest that, rather than to the intensity of
injury, the cytotoxic chronic activity of microglia contributes
to the growth of affected areas during neurodegeneration. As
the increased area of S100B-IR may not be translated into
increased S100B release and could just reflect astrocytosis,
further experiments are needed to quantify in vivo the S100B
release long after an excitotoxic insult and characterize its
effects on microglia inflammatory activity.
5. Conclusions
In conclusion, in this paper we show that NMDA-induced
excitotoxicity in the hippocampus induces a chronic mi-
crogliosis. In this model, an initial release of YM1 followed
by TNF-𝛼 production and the transient activation of GR
may determine a putative functional switch of microglia.
Although a role for infiltrated neutrophils and macrophages
must not be ruled out, the astroglial removal in the early
stages of the lesion may potentiate an initial neuroprotective
role of microgliosis and reveals the S100B as a key modulator
of microglia phenotype. These results also contribute to
understanding the interplay between the trophic, neuropro-
tective, inflammatory, and cytotoxic functions of astrocytes
and microglia during the course of brain injury. The fine
control of these processes requires a dynamic understand-
ing of their interactions to allow effective development of
approaches to neuroprotection.
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